We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Nogo-A and LINGO-1: Two Important Targets for Remyelination and Regeneration.
- Authors
Kalafatakis, Ilias; Papagianni, Fevronia; Theodorakis, Konstantinos; Karagogeos, Domna
- Abstract
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system (CNS) that causes progressive neurological disability in most patients due to neurodegeneration. Activated immune cells infiltrate the CNS, triggering an inflammatory cascade that leads to demyelination and axonal injury. Non-inflammatory mechanisms are also involved in axonal degeneration, although they are not fully elucidated yet. Current therapies focus on immunosuppression; however, no therapies to promote regeneration, myelin repair, or maintenance are currently available. Two different negative regulators of myelination have been proposed as promising targets to induce remyelination and regeneration, namely the Nogo-A and LINGO-1 proteins. Although Nogo-A was first discovered as a potent neurite outgrowth inhibitor in the CNS, it has emerged as a multifunctional protein. It is involved in numerous developmental processes and is necessary for shaping and later maintaining CNS structure and functionality. However, the growth-restricting properties of Nogo-A have negative effects on CNS injury or disease. LINGO-1 is also an inhibitor of neurite outgrowth, axonal regeneration, oligodendrocyte differentiation, and myelin production. Inhibiting the actions of Nogo-A or LINGO-1 promotes remyelination both in vitro and in vivo, while Nogo-A or LINGO-1 antagonists have been suggested as promising therapeutic approaches for demyelinating diseases. In this review, we focus on these two negative regulators of myelination while also providing an overview of the available data on the effects of Nogo-A and LINGO-1 inhibition on oligodendrocyte differentiation and remyelination.
- Subjects
NOGO protein; OLIGODENDROGLIA; CENTRAL nervous system diseases; DEMYELINATION; MULTIPLE sclerosis; THERAPEUTICS
- Publication
International Journal of Molecular Sciences, 2023, Vol 24, Issue 5, p4479
- ISSN
1661-6596
- Publication type
Article
- DOI
10.3390/ijms24054479